Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma

Journal of Translational Medicine

Andre Luiz Vettore³  Cristovam Scapulatempo-Neto¹  André Lopes Carvalho²  Maria Aderuza Horst⁵  Ana Carolina de Carvalho⁴  Danielle Maia⁵ 

[1] Department of Pathology, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos 14784-400, Brazil;Department of Head and Neck Surgery, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos 14784-400, Brazil;Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore, Singapore;Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331, Barretos 14784-400, SP, Brazil;Laboratory of Molecular Cancer Biology, Department of Biological Sciences, Federal University of São Paulo, Rua Pedro de Toledo, 669-11° andar, São Paulo 04039-032, SP, Brazil

关键词: miR-296-5p;    Radioresistance;    MicroRNAs;    Molecular marker;    Early-stage laryngeal cancers;   

Others  :  1235225
DOI  :  10.1186/s12967-015-0621-y

 received in 2015-03-08, accepted in 2015-07-28,  发布年份 2015

【 摘 要 】

Purpose

Definitive radiation therapy is the mainstay of treatment for early stage laryngeal squamous cell carcinoma (LSCC). However, up to 30% of the patients do not respond to radiotherapy. Unfortunately, we are unable to predict which tumors are likely to respond to radiation, and which will be resistant and persist. Therefore, the development of novel markers to predict response to radiotherapy is urgently needed. This study was designed to evaluate the expression pattern of microRNAs (miRNAs) in LSCC in order to identify markers capable of segregating radioresistant and radiosensitive tumors and to investigate the relationship between the expression of these miRNAs and the prognosis of LSCC.

Methods

The expression profile of 667 miRNAs was determined in an initial screening of nine early-stage LSCC samples (5 radioresistant and 4 radiosensitive) using TaqMan Low-Density Array (TLDA). Real-time polymerase chain reactions were performed to validate the expression of selected miRNAs in an expanded LSCC cohort (20 radioresistant and 14 radiosensitive). The miRNA expression level was scored as high or low based on the median of the expression in the LSCC samples.

Results

A comprehensive miRNA expression profiling enabled the identification of four miRNAs (miR-296-5p miR-452, miR-183* and miR-200c) differentially expressed in radioresistant LSCC. Moreover, the analysis of additional 34 LSCC samples, confirmed the expression of miR-296-5p as significantly related to radioresistance (p = 0.002) as well as an association of this marker with recurrence (p = 0.025) in early stage laryngeal cancer.

Conclusions

This study indicates that miR-296-5p expression is associated with resistance to radiotherapy and tumor recurrence in early stage LSCC, showing the feasibility of this marker as a novel prognostic factor for this malignance. Furthermore, miR-296-5p expression could be helpful in the identification of tumors resistant to radiotherapy; thus aiding the clinicians in the choice of the best therapeutic scheme to be used in each case.

【 授权许可】

   
2015 Maia et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010; 2010:2893-2917.
• [2]Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. IARC Press, Lyon; 2005.
• [3]Pfister D, Laurie S, Weinstein G, Mendenhall WM, Adelstein D, Ang K et al.. American Society of Clinical Oncology Clinical Practice Guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; 24(22):3693-3704.
• [4]Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ et al.. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; 24:3693-3704.
• [5]Cosetti M, Yu G-P, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008; 134:370-379.
• [6]Hera BHSC, Mdur ROJA, Orris CHGM, Irwan JEMK, Endenhall WIMM. T1N0 and T2N0 Squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Radiat Oncol. 2010; 78:461-466.
• [7]Aarts MCJ, Rovers MM, Grau C, Grolman W, van der Heijden GJM. Salvage laryngectomy after primary radiotherapy: what are prognostic factors for the development of pharyngocutaneous fistulae? Otolaryngol Head Neck Surg Off J Am Acad Otolaryngol Head Neck Surg. 2011; 144:5-9.
• [8]Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006; 64:77-82.
• [9]Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol. 2012; 22:108-118.
• [10]Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007; 68:654-661.
• [11]Rosenthal DI, Ang KK. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol. 2004; 2:153-166.
• [12]Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al.. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12:1004-1012.
• [13]Köhne C-H (2010) How to integrate molecular targeted agents in the continuum of care. Ann Oncol 21(Suppl 7):vii134–vii139
• [14]Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C et al.. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14:38-47.
• [15]Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al.. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13:1011-1019.
• [16]Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD et al.. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012; 13:366-374.
• [17]He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522-531.
• [18]Bartel DP, Lee R, Feinbaum R. MicroRNAs: genomics, biogenesis, mechanism, and function genomics: the miRNA genes. Cell. 2004; 116:281-297.
• [19]Jin T, Lin HX, Lin H, Guo LB, Ge N, Cai XY et al.. Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: a retrospective study. J Transl Med. 2012; 10:64. BioMed Central Full Text
• [20]Kumar B, Cordell KG, D’Silva N, Prince ME, Adams ME, Fisher SG et al.. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008; 134:363-369.
• [21]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al.. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
• [22]AJCC cancer staging manual. 5th ed. Springer, New York; 1997.
• [23]Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008; 3:1101-1108.
• [24]Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W et al.. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res. 2010; 16:1129-1139.
• [25]Petrash HA, Philbrook A, Haburcak M, Barbagallo B, Francis MM. ACR-12 ionotropic acetylcholine receptor complexes regulate inhibitory motor neuron activity in Caenorhabditis elegans. J Neurosci. 2013; 33:5524-5532.
• [26]Brown JS, Shaw RJ. Reconstruction of the maxilla and midface: introducing a new classification. Lancet Oncol. 2010; 11:1001-1008.
• [27]Papagikos MA, Shaw EG, Stieber VW. Lessons learned from randomised clinical trials in adult low grade glioma. Lancet Oncol. 2005; 6:240-244.
• [28]Schimming R, Reusch P, Kuschnierz J, Schmelzeisen R. Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg. 2004; 32:176-181.
• [29]Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E et al.. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol. 2011; 225:43-53.
• [30]Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M et al.. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 2009; 174:736-745.
• [31]Caltabiano R, Barbagallo GM, Castaing M, Cassenti A, Senetta R, Cassoni P et al.. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study. J Neurosurg Sci. 2013; 57:139-151.
• [32]Fletcher AM, Heaford AC, Trask DK. Detection of metastatic head and neck squamous cell carcinoma using the relative expression of miR-205. Oncology. 2008; 1:202-208.
• [33]Ayaz L, Gorur A, Yaroglu HY, Ozcan C, Tamer L. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2013; 139:1499-1506.
• [34]Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D et al.. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013; 35(5):720-728.
• [35]Ghotra VP, Puigvert JC, Danen EH. The cancer stem cell microenvironment and anti-cancer therapy. Int J Radiat Biol. 2009; 85:955-962.
• [36]Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. 2006; 10:454-456.
• [37]Huang CX, Zhu Y, Duan GL, Yao JF, Li ZY, Li D et al.. Screening for MiRNAs related to laryngeal squamous carcinoma stem cell radiation. Asian Pac J Cancer Prev. 2013; 14:4533-4537.
• [38]Maduri R, Barbagallo G, Iofrida G, Signorelli M, Signorelli F. Regression of Benedikt’s syndrome after single-stage removal of mesencephalic cavernoma and temporal meningioma: a case report. Clin Neurol Neurosurg. 2013; 115:748-750.
• [39]Su H, Jin X, Zhang X, Xue S, Deng X, Shen L et al.. Identification of microRNAs involved in the radioresistance of esophageal cancer cells. Cell Biol Int. 2014; 38:318-325.
• [40]Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R et al.. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene. 2013; 32:2848-2857.
• [41]Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 2010; 76:5-8.
• [42]Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B et al.. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013; 4:e544.
• [43]Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J et al.. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008; 14:382-393.
• [44]Wang S, Olson EN. AngiomiRs—key regulators of angiogenesis. Curr Opin Genet Dev. 2009; 19:205-211.
• [45]Barbagallo D, Piro S, Condorelli AG, Mascali LG, Urbano F, Parrinello N et al.. miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic alpha cells to cytokine-induced apoptosis as compared to beta cells. BMC Genom. 2013; 14:62. BioMed Central Full Text
• [46]Hong L, Han Y, Zhang H, Li M, Gong T, Sun L et al.. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010; 251:1056-1063.